未登录

T

Thomas T. Poulsen

symphogen

H指数:17

被引数:941

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer

MOLECULAR CANCER THERAPEUTICS

IF5.5

2019-11-0146

OAAI

CD4+ and CD8a+ PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer models

IF13.3

2019-01-0165

OAAI

Protein pathway activation analysis of a panel of patient-derived epithelial tumor models identifies signatures of response to ErbB1-3 co-targeting

CANCER RESEARCH

IF16.6

2018-07-010

PRE

CD4+ and CD8a+ PET imaging in syngeneic mouse models for prediction of immuno-therapeutic response

在同系小鼠模型中预测免疫治疗反应的CD4和CD8a PET成像

CANCER RESEARCH

IF16.6

2018-07-010

PRE

Acquired Resistance to a MET Antibody In Vivo Can Be Overcome by the MET Antibody Mixture Sym015

MOLECULAR CANCER THERAPEUTICS

IF5.5

2018-05-319

OAAI

Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple Mechanisms

MOLECULAR CANCER THERAPEUTICS

IF5.5

2017-12-0324

OA

In vivo acquired resistance to an emibetuzumab analogue in MET-amplified gastric xenografts can be overcome by a MET-targeting antibody mixture or PIK3CA/AKT/mTOR inhibition

CANCER RESEARCH

IF16.6

2017-07-010

PRE

Is the supply chain ready for the green transformation? The case of offshore wind logistics

供应链是否为绿色转型做好了准备？海上风电物流案例:

RENEWABLE & SUSTAINABLE ENERGY REVIEWS

IF16.3

2017-06-0156

OAAI

Pan-HERAn antibody mixture targeting EGFR, HER2 and HER3 abrogates preformed and ligand-induced EGFR homo- and heterodimers

INTERNATIONAL JOURNAL OF CANCER

IF4.7

2016-07-1920

OAAI

A novel synergistic antibody pair targeting non-overlapping epitopes of MET effectively inhibits MET-driven cancer models

CANCER RESEARCH

IF16.6

2016-07-150

PRE

Sym015, a novel antibody mixture targeting non-overlapping epitopes of MET, effectively inhibits growth of MET dependent tumors and overcomes resistance to a single monoclonal antibody

CANCER RESEARCH

IF16.6

2016-07-151

PRE

Effective targeting of colorectal cancer with a recombinant antibody mixture against EGFR, HER3 and IGF1R

CANCER RESEARCH

IF16.6

2015-08-010

PRE

Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance

MOLECULAR CANCER THERAPEUTICS

IF5.5

2015-03-0953

OAAI

Effect of antibody mixtures on HER-family heterodimerization

CANCER RESEARCH

IF16.6

2014-10-010

PRE

Simultaneous inhibition of HER-family receptors by Pan-HER antibody mixture prevents compensatory HER-family receptor upregulation and induces cell death in a broad range of tumor models

CANCER RESEARCH

IF16.6

2014-10-010

PRE

In vivo imaging of therapy response to novel antibody mixtures targeted at the human epidermal growth factor receptor family using FDG and FLT positron emission tomography

CANCER RESEARCH

IF16.6

2014-10-010

PRE

Simultaneous inhibition of EGFR, HER2 and HER3 by an antibody mixture provides broad and potent tumor inhibition

CANCER RESEARCH

IF16.6

2013-04-010

PRE

Insertion of a nuclear factor kappa B DNA nuclear-targeting sequence potentiates suicide gene therapy efficacy in lung cancer cell lines

CANCER GENE THERAPY

IF5

2012-08-1721

OA

Single agent- and combination treatment with two targeted suicide gene therapy systems is effective in chemoresistant small cell lung cancer cells

JOURNAL OF GENE MEDICINE

IF2.2

2012-07-2517

PREAI

Suicide gene therapy is effective for treating chemo-resistant small cell lung cancer cells

CANCER RESEARCH

IF16.6

2012-04-010

PRE